Tag: Sexually Transmitted Diseases: AIDS/HIV
Fostemsavir Active in Multidrug-Resistant HIV-1 Infection
Reduction in HIV-1 RNA level significantly greater for fostemsavir versus placebo in randomized cohort
Second Case of HIV-1 Cure After Stem Cell Transplant Reported
HIV-1 viral load remained undetectable in plasma in patient up to 30 months after transplant
New HIV PrEP Drug Not Cost-Effective Compared With Generic
F/TAF would avert 2,101 fractures, 25 cases of end-stage renal disease, but not deemed cost-effective
Long-Acting Cabotegravir, Rilpivirine Noninferior in HIV-1
Studies demonstrate noninferiority to standard oral therapy, dolutegravir-abacavir-lamivudine
February 2020 Briefing – HIV & AIDS
Here are what the editors at HealthDay consider to be the most important developments in HIV & AIDS for February 2020. This roundup includes...
HIV-Infected Youth Less Likely to Achieve Viral Suppression
Findings seen in large national sample of youth despite similar rates of linkage to care as adults
COPD Incidence Higher in People With HIV
People with HIV have 34 percent higher rate of COPD than those without; smoking may be to blame
Few Adolescent Men Who Have Sex With Men Have Had HIV Test
Most have regular doctor, but few have had conversations about same-sex sexual behaviors, HIV testing
Adding Maraviroc to c-ART No Better in Advanced HIV
Incidence of severe morbidity similar for addition of maraviroc versus placebo to standard c-ART
Costs of ART Regimens Increasing, Outpacing Inflation
Annual average wholesale price of initial ART regimens recommended for most persons with HIV >$36,000
